Clozapine monitoring requirements: is it time for an update?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39359180.
- Also identified by DOI 10.1192/bjp.2024.150.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Oloyede and colleagues advocate for updating haematological monitoring requirements for clozapine, arguing that current protocols overestimate the risk of clozapine-induced agranulocytosis. Their research suggests that stringent monitoring may unnecessarily limit access to clozapine, a crucial treatment for resistant schizophrenia. The editorial supports calls for international consensus to carefully weigh the pros and cons of relaxing monitoring guidelines while ensuring comprehensive care for patients.
Medical subject headings
- Clozapine
- Antipsychotic Agents
- Drug Monitoring
- Agranulocytosis
- Schizophrenia
- Schizophrenia, Treatment-Resistant